Jiangsu Hengrui Medicine Co., Ltd.

SHSE:600276 Stock Report

Market Cap: CN¥294.1b

Jiangsu Hengrui Medicine Balance Sheet Health

Financial Health criteria checks 6/6

Jiangsu Hengrui Medicine has a total shareholder equity of CN¥44.3B and total debt of CN¥0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CN¥48.3B and CN¥4.0B respectively. Jiangsu Hengrui Medicine's EBIT is CN¥5.5B making its interest coverage ratio -8.9. It has cash and short-term investments of CN¥22.9B.

Key information

0%

Debt to equity ratio

CN¥0

Debt

Interest coverage ratio-8.9x
CashCN¥22.91b
EquityCN¥44.33b
Total liabilitiesCN¥4.01b
Total assetsCN¥48.34b

Recent financial health updates

No updates

Recent updates

Getting In Cheap On Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Might Be Difficult

Oct 25
Getting In Cheap On Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276) Might Be Difficult

Calculating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)

Oct 07
Calculating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)

Revenue Beat: Jiangsu Hengrui Medicine Co., Ltd. Exceeded Revenue Forecasts By 12% And Analysts Are Updating Their Estimates

Aug 23
Revenue Beat: Jiangsu Hengrui Medicine Co., Ltd. Exceeded Revenue Forecasts By 12% And Analysts Are Updating Their Estimates

Why We're Not Concerned About Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Share Price

Jul 03
Why We're Not Concerned About Jiangsu Hengrui Medicine Co., Ltd.'s (SHSE:600276) Share Price

Estimating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)

May 22
Estimating The Fair Value Of Jiangsu Hengrui Medicine Co., Ltd. (SHSE:600276)

Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Seem To Be Promising

Apr 24
Jiangsu Hengrui Medicine's (SHSE:600276) Earnings Seem To Be Promising

Financial Position Analysis

Short Term Liabilities: 600276's short term assets (CN¥34.5B) exceed its short term liabilities (CN¥3.8B).

Long Term Liabilities: 600276's short term assets (CN¥34.5B) exceed its long term liabilities (CN¥177.0M).


Debt to Equity History and Analysis

Debt Level: 600276 is debt free.

Reducing Debt: 600276 had no debt 5 years ago.

Debt Coverage: 600276 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 600276 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 04:50
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jiangsu Hengrui Medicine Co., Ltd. is covered by 65 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ling ZhangBNP Paribas Securities (Asia)
Changming HeBOCI Research Ltd.
Bo LiBofA Global Research